Innovating Works

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Inactiva
Mostrando 1 al 20 de 126 resultados
MENTOR: Metabolic control of cell growth by mTOR in health and disease a multi disciplinary training MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cue...
2024-07-09 - 2028-12-31 | Financiado
HD-BRECA: Integrating longitudinal multi-modal profiling of metastatic breast cancer patients for high-definit... FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Precision Oncology has revolutionized cancer therapeutics, mostly by matching genomic alterations with molecularly targeted agents. Yet, cur...
2024-04-18 - 2026-05-31 | Financiado
INN-TIME: Co-option of host circadian rhythms in cancer FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un HORIZON EUROPE: ERC-2023-STG Circadian rhythms (CRs) are the biological response to the periodic rotations of the Earth, and allow fundamental adaptations of organisms t...
2023-12-15 - 2029-02-28 | Financiado
GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF tramitó un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado
NutFLirsFA: NUTRIENT FLUCTUATIONS AND THE INTEGRATIVE STRESS RESPONSE AS METABOLIC CELL FATE DETERMINANTS IN B C... FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Metabolic reprogramming enables cells to adopt different phenotypes, providing flexibility in response to environmental stress, of particula...
2023-04-28 - 2026-08-31 | Financiado
WAC-mTOR-OC: Targeting R2TP/TTT/WAC/mTOR complex in ovarian cancer. FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Ovarian Cancer (OC) is the most lethal gynecological tumor and has an especially high impact in Europe. 70% of patients develop an advanced...
2023-04-21 - 2026-08-31 | Financiado
PANCAID: PANcreatic CAncer Initial Detection via liquid biopsy UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF tramitó un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will theref...
2022-12-02 - 2027-12-31 | Financiado
TargetRANK: Targeting RANK receptor as a novel therapeutic strategy in triple negative breast cancer FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un HORIZON EUROPE: ERC-2022-POC1 Breast cancer is the most common malignancy among females in the western world, resulting in nearly half a million deaths annually, mainly d...
2022-06-13 - 2024-08-31 | Financiado
EOSC4Cancer: A European wide foundation to accelerate Data driven Cancer Research BARCELONA SUPERCOMPUTING CENTERCENTRO NACIONAL DE SUPERCOMPUTACION tramitó un HORIZON EUROPE: HORIZON-INFRA-2021-EOSC-01 Cancer complex nature requires integration of advanced research data across national boundaries to enable progress. Indeed, the Horizon Euro...
2022-06-09 - 2025-02-28 | Financiado
MADRIDNIGHT: Researchers and citizens facing together the European challenges FUNDACION PARA EL CONOCIMIENTO MADRID+D tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-CITIZENS-01 The European Researchers' Night in Madrid will bring together researchers to the general public and will increase awareness of the importanc...
2022-04-21 - 2024-04-30 | Financiado
MAtChinG: Mechanically Activated Channels in Glioma the role of mechanoreceptor Piezo1 and hnRNP K in cancer... FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un H2020: H2020-MSCA-IF-2020 Glioblastoma multiforme (GBM) is one of the most common and aggressive forms of brain tumour, affecting 2-3 per 100,000 adults per year, and...
2021-04-27 - 2023-08-31 | Financiado
BREASTCANCERSTEM: The CD44 RANK AKT Crosstalk in Breast Cancer and Stemness FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un H2020: H2020-MSCA-IF-2020 Relapse and metastasis in cancer are driven by cancer stem cells (CSC) which self-renew, give rise to tumor cell heterogeneity and are more...
2021-04-16 - 2022-10-06 | Financiado
TARGETSET: Commercial feasibility of targeting the histone methyltransferase SETD8 in cancer New chemical enti... FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III tramitó un H2020: ERC-2020-PoC Within our ERC CoG grant, RSHEALTH, our group has contributed to the to the preclinical development of chemical inhibitors of the ATR kinase...
2021-02-02 - 2022-12-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.